tiprankstipranks
Trending News
More News >
AnaptysBio’s Promising Phase 2 Trial Results and Strategic Plans Lead to Stock Upgrade
PremiumRatingsAnaptysBio’s Promising Phase 2 Trial Results and Strategic Plans Lead to Stock Upgrade
19d ago
AnaptysBio upgraded to Buy from Neutral at H.C. Wainwright
Premium
The Fly
AnaptysBio upgraded to Buy from Neutral at H.C. Wainwright
19d ago
Promising Potential of AnaptysBio’s Rosnilimab: A Buy Rating Backed by Strong Phase 2b Trial Results and Strategic Outlook
Premium
Ratings
Promising Potential of AnaptysBio’s Rosnilimab: A Buy Rating Backed by Strong Phase 2b Trial Results and Strategic Outlook
19d ago
AnaptysBio Reports Strong Q1 2025 Results and Progress
PremiumCompany AnnouncementsAnaptysBio Reports Strong Q1 2025 Results and Progress
1M ago
AnaptysBio price target raised to $54 from $52 at Guggenheim
Premium
The Fly
AnaptysBio price target raised to $54 from $52 at Guggenheim
2M ago
Hold Rating for AnaptysBio Amid Uncertainties in Clinical Trial Data and Market Position
Premium
Ratings
Hold Rating for AnaptysBio Amid Uncertainties in Clinical Trial Data and Market Position
2M ago
AnaptysBio sees cash runway through year-end 2027
PremiumThe FlyAnaptysBio sees cash runway through year-end 2027
3M ago
Wells Fargo Predicts Up to ~440% Rally for These 2 ‘Strong Buy’ Stocks
Premium
Stock Analysis & Ideas
Wells Fargo Predicts Up to ~440% Rally for These 2 ‘Strong Buy’ Stocks
3M ago
AnaptysBio price target raised to $42 from $36 at JPMorgan
Premium
The Fly
AnaptysBio price target raised to $42 from $36 at JPMorgan
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100